Sustainable therapeutics via synthetic biology
Small molecule-based cancer therapeutics that outperform high-cost biologics and engineered cells
Cancer cells grow out of control. They keep dividing when healthy cells would normally be quiescent. By nailing down the key biological differences between cancer and normal cells, PRUNUS is pioneering a new way of treating cancer.
PRUNUS’ platform AcK-Lock prodrug technology is designed to protect healthy cells from off-target effects by selectively releasing active agents in a wide range of cancer cells.
PRUNUS takes bold steps for the future healthcare. We believe that our unique programs would lead to new precision therapeutics & diagnostics that may dramatically improve the treatment outcome as well as quality of life.
PRUNUS Therapeutics is a Chicagoland-based biotech startup launched in 2016. PRUNUS’ main platform focuses on sustainable cancer therapeutics based on its proprietary AcK-Lock prodrug technology. AcK-Lock is designed to address off-target effects on healthy cells by selectively releasing active agents in a wide range of cancer cells. PRUNUS' pipeline products include small molecules, targeted protein/RNA degraders, biologics, vaccines, and companion diagnostic tests.